New Jersey Senator diagnosed with lymphoma
The office of United States Senator Frank Lautenberg, an 86 year old Democrat from New Jersey, announced on Friday that the congressman has been diagnosed with non-Hodgkin's lymphoma and is receiving treatment at a New York City area hospital. The announcement said the Senator's diagnosis was of a 'B-cell lymphoma of the stomach' but it wasn't any more specific than that with regard to subtype.
Since the Senator was recently treated for a bleeding ulcer, it would suggest that he has been diagnosed with MALT lymphoma, since both are caused by the bacteria Helicobacter pylori. However, the announcement said his treatment has included chemotherapy every three weeks, while MALT lymphoma is generally treated with antibiotics, not chemotherapy.
According to the statement, the Senator is expected to make a full recovery.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
